Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement

BMC Musculoskeletal Disorders

Jing-nan Shen²  Jin wang²  Gang Huang²  Chang-ye Zou²  Xian-biao Xie²  Jun-qiang Yin²  Zhen-hua Gao¹ 

[1] Department of Radiology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China;Department of Orthopaedics, First Affiliated Hospital of Sun Yat-Sen University, 58# zhongshan 2 road, Guangzhou 510080, P.R. China

关键词: Local recurrence;    Aggressive curettage;    Bone cement;    Bone graft;    Giant cell tumor of the long bone;   

Others  :  1122002
DOI  :  10.1186/1471-2474-15-330

 received in 2014-03-19, accepted in 2014-09-19,  发布年份 2014

【 摘 要 】

Background

Aggressive curettage has been well established for the treatment of giant cell tumors (GCTs) of the bone. The purpose of this study was to review our experience and evaluate the role of different implant materials in patients with GCTs of the extremities after aggressive curettage.

Methods

A total of 119 patients with GCTs of the long bone were treated at the First Affiliated Hospital of Sun Yat-Sen University between 2004 and 2009. We excluded patients presenting metastases, recurrent tumors, and soft tissue involvement and those with Jaffe pathological grade III. The remaining 65 patients were treated with aggressive curettage using a bone graft or bone cement to fill the cavity. The recurrence rates and functional scores associated with the different fillings were analyzed.

Results

Aggressive curettage and bone grafting was performed in 34 cases (52.3%), and aggressive curettage with bone cement was performed in 31 cases (47.7%). The overall recurrence rate after the aggressive intralesional procedures was 35.3% with bone grafting and 12.9% when bone cement was used as an adjuvant filling. The recurrence rate following aggressive curettage and bone grafting was higher than that following aggressive curettage with cement (p = 0.038). The Musculoskeletal Tumor Society (MSTS) score for bone graft patients was 91.1%, which was significantly lower than that for patients treated with bone cement (94.7%).

Conclusions

The use of bone cement was associated with a significantly lower recurrence rate than bone grafting following aggressive intralesional curettage to treat benign giant cell tumors of the long bone. Better MSTS functional results were also observed in the bone cement group compared to the bone graft group.

【 授权许可】

   
2014 Gao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 2.

【 参考文献 】

• [1]Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am 1987, 69:106-114.
• [2]Yasko AW: Giant cell tumor of bone. Curr Oncol Rep 2002, 4:520-526.
• [3]Domovitov SV, Healey JH: Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol 2010, 17:694-701.
• [4]Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP: Giant cell tumor of bone. Am J Clin Oncol 2006, 29:96-99.
• [5]Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ: Giant cell tumor of bone. J Am Acad Orthop Surg 2013, 21:118-126.
• [6]Campanacci M, Capanna R, Fabbri N, Bettelli G: Curettage of giant cell tumor of bone. Reconstruction with subchondral grafts and cement. Chir Organi Mov 1990, 75:212-213.
• [7]Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G: Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008, 134:969-978.
• [8]Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P, Folleras G: Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008, 79:86-93.
• [9]Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH: Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011, 469:591-599.
• [10]Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS: Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999, 81:811-820.
• [11]Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM: Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002, 397:248-258.
• [12]Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H, Liu W: Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 2012, 94:461-467.
• [13]Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, Hovy L, Matejovsky Z, Szendroi M, Trieb K, Tunn PU: Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008, 90:1060-1067.
• [14]Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M: Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 2010, 36:1-7.
• [15]JaVe HL, Lichtenstein L, Portis RB: Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol 1940, 30:993-1031.
• [16]Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996, 14:848-858.
• [17]Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ: A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res 1993, 286:241-246.
• [18]Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E: The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001, 127:467-474.
• [19]Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr: Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics 2013, 33:197-211.
• [20]Goldring SR, Schiller AL, Mankin HJ, Dayer JM, Krane SM: Characterization of cells from human giant cell tumors of bone. Clin Orthop Relat Res 1986, 204:59-75.
• [21]Cowan RW, Singh G: Giant cell tumor of bone: a basic science perspective. Bone 2013, 52:238-246.
• [22]Scully SP, Mott MP, Temple HT, O’Keefe RJ, O’Donnell RJ, Mankin HJ: Late recurrence of giant-cell tumor of bone. A report of four cases. J Bone Joint Surg Am 1994, 76:1231-1233.
• [23]Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R: Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001, 27:200-202.
• [24]Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ: Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone. Clin Orthop Relat Res 2005, 435:211-218.
• [25]Wang HC, Chien SH, Lin GT: Management of grade III giant cell tumors of bones. J Surg Oncol 2005, 92:46-51.
• [26]Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O’Donnell RJ: Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop 2006, 30:495-498.
• [27]Szendroi M, Kiss J, Antal I: Surgical treatment and prognostic factors in giant-cell tumor of bone. Acta Chir Orthop Traumatol Cech 2003, 70:142-150.
• [28]Krishnan EC, Nelson C, Neff JR: Thermodynamic considerations of acrylic cement implant at the site of giant cell tumors of the bone. Med Phys 1986, 13:233-239.
• [29]Nelson DA, Barker ME, Hamlin BH: Thermal effects of acrylic cementation at bone tumour sites. Int J Hyperthermia 1997, 13:287-306.
• [30]Sakayama K, Sugawara Y, Kidani T, Miyawaki J, Fujibuchi T, Kamei S, Aizawa J, Yamamoto H: Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg 2007, 127:867-872.